Jump Financial LLC Cuts Stock Position in Kura Oncology, Inc. $KURA

Key Points

• Jump Financial LLC reduced its stake in Kura Oncology by 19.7%, now holding approximately 0.22% of the company worth $1.27 million.
• Kura Oncology's stock experienced a 2.7% increase in trading, opening at $8.07, with a 12-month range from $5.41 to $21.57.
• Analyst recommendations vary, with a consensus rating of "Moderate Buy" and an average price target of $24.10 for Kura Oncology shares.

Jump Financial LLC decreased its stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 19.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 192,711 shares of the company's stock after selling 47,222 shares during the period. Jump Financial LLC owned 0.22% of Kura Oncology worth $1,272,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Pallas Capital Advisors LLC acquired a new stake in Kura Oncology during the first quarter worth approximately $66,000. Corton Capital Inc. acquired a new stake in Kura Oncology during the fourth quarter worth approximately $99,000. Flower City Capital acquired a new stake in Kura Oncology during the first quarter worth approximately $79,000. E Fund Management Co. Ltd. grew its stake in Kura Oncology by 18.9% during the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock worth $81,000 after purchasing an additional 1,951 shares during the period. Finally, Ameriprise Financial Inc. bought a new position in Kura Oncology in the fourth quarter worth approximately $130,000.

Kura Oncology Stock Up 4.3%

KURA stock traded up $0.35 during midday trading on Wednesday, hitting $8.30. The company's stock had a trading volume of 379,018 shares, compared to its average volume of 1,458,112. The company has a market cap of $720.01 million, a PE ratio of -3.67 and a beta of 0.19. Kura Oncology, Inc. has a 12 month low of $5.41 and a 12 month high of $21.40. The company has a current ratio of 6.16, a quick ratio of 6.16 and a debt-to-equity ratio of 0.02. The firm's 50-day moving average is $6.51 and its 200-day moving average is $6.57.

Kura Oncology (NASDAQ:KURA - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported ($0.75) earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million during the quarter, compared to analysts' expectations of $64.95 million. On average, equities research analysts forecast that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

KURA has been the topic of several recent research reports. JMP Securities cut their price target on Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating on the stock in a report on Monday, August 11th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Kura Oncology in a report on Thursday, June 26th. Wall Street Zen upgraded Kura Oncology from a "sell" rating to a "hold" rating in a report on Sunday, August 17th. Mizuho cut their price target on Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a research note on Monday, May 19th. Finally, Wedbush restated an "outperform" rating and set a $36.00 target price on shares of Kura Oncology in a research report on Friday, June 20th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat.com, Kura Oncology has a consensus rating of "Moderate Buy" and an average target price of $24.10.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.